Hetero's COVID-19 oral drug Nirmacom gets WHO prequalification

WHO made a strong recommendation for Nirmatrelvir and Ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission.

Hetero, a city-based leading pharmaceutical company on Monday announced the receipt of World Health Organisation Prequalification of Medicines Programme (WHO PQ) approval for its generic version of COVID-19 oral anti-viral treatment candidate Nirmatrelvir.

A press release from the drug maker said it is the first prequalification for a generic version of Pfizer's COVID-19 oral anti-viral drug 'Paxlovid,' which the WHO called, the best therapeutic choice for high-risk patients to date.

WHO made a strong recommendation for Nirmatrelvir and Ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission, such as unvaccinated, aged or immunosuppressed patients, it said.

The combi pack, launched by Hetero as Nirmacom, will contain Nirmatrelvir 150 mg (2 tablets) and Ritonavir 100mg (1 tablet). It is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Nirmacom will be manufactured at Hetero's facilities in India, the release said.

Vamsi Krishna Bandi, Managing Director, Hetero Group of Companies, said, "WHO Prequalification for Nirmacom is a significant milestone in the fight against COVID-19 as it allows us to expand access to this important innovative antiretroviral drug to people in need. We are committed to making Nirmacom available faster at affordable prices across 95 LMICs including India."

Hetero entered into a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) for manufacturing and sale of a generic version of Pfizer's COVID-19 oral anti-viral treatment candidate Nirmatrelvir, which is co-packaged with Ritonavir (Nirmatrelvir; Ritonavir), in LMICs (low and middle income countries).